Literature DB >> 2213760

Prevalence and concentration of IgM rheumatoid factor in polyarticular onset disease as compared to systemic or pauciarticular onset disease in active juvenile rheumatoid arthritis as measured by ELISA.

S M Walker1, B Shaham, D K McCrudy, H Wietting, Y K Arora, V Hanson, B Bernstein.   

Abstract

The prevalence and concentration of IgM rheumatoid factor (RF) in children with juvenile rheumatoid arthritis (JRA) and its major disease onset groups remains uncertain. In our study enzyme linked immunoabsorbent assay (ELISA) of 68 children with active JRA showed IgM RF in the area of 67% (16/24) of those with polyarticular onset disease, 26% (7/27) of those with systemic onset disease, and 6% (1/17) of those with pauciarticular onset disease. The median IgM RF concentration was 50-fold higher in polyarticular disease compared to systemic disease. The prevalence of IgM RF in polyarticular disease was greater in those with severe disease (functional classes and 3 and 4), with 90% (9/10) seropositive. By agglutination assay, the prevalence of IgM RF in JRA was significantly less than by ELISA, with 33% of the polyarticular group positive for IgM RF, and none of the systemic group positive, Relatively low concentration IgM RF similar to that seen in systemic JRA was also found in high prevalence in the area of children with non-JRA, systemic rheumatic disease (n = 8). In summary, our study shows by ELISA that high concentrations of IgM RF are found essentially only in the sera of children with polyarticular onset JRA and especially in those with severe disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2213760

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  8 in total

1.  Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states.

Authors:  Claudia Macaubas; Khoa Nguyen; Chetan Deshpande; Carolyn Phillips; Ariana Peck; Tzielan Lee; Jane L Park; Christy Sandborg; Elizabeth D Mellins
Journal:  Clin Immunol       Date:  2009-10-29       Impact factor: 3.969

2.  Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment].

Authors:  S Takei; Y K Arora; S M Walker
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

3.  Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha production.

Authors:  T Darville; L B Milligan; K K Laffoon
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

4.  Is measurement of IgM and IgA rheumatoid factors (RF) in juvenile rheumatoid arthritis clinically useful?

Authors:  Rosa A Ferreira; Carlos H M Silva; Deise A O Silva; Monica C Sopelete; Maria H B Kiss; Jose R Mineo; Virginia P L Ferriani
Journal:  Rheumatol Int       Date:  2006-09-29       Impact factor: 2.631

5.  Serum IgM rheumatoid factor by enzyme-linked immunosorbent assay (ELISA) delineates a subset of patients with deforming joint disease in seronegative juvenile rheumatoid arthritis.

Authors:  A Aggarwal; S Dabadghao; S Naik; R Misra
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

Review 6.  Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology.

Authors:  Reema H Syed; Brooke E Gilliam; Terry L Moore
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

7.  Development of positive antinuclear antibodies and rheumatoid factor in systemic juvenile idiopathic arthritis points toward an autoimmune phenotype later in the disease course.

Authors:  Boris Hügle; Claas Hinze; Elke Lainka; Nadine Fischer; Johannes-Peter Haas
Journal:  Pediatr Rheumatol Online J       Date:  2014-07-16       Impact factor: 3.054

Review 8.  Autoantibodies and their Judicious Use in Pediatric Rheumatology Practice.

Authors:  Biman Saikia; Amit Rawat; Pandiarajan Vignesh
Journal:  Indian J Pediatr       Date:  2015-12-03       Impact factor: 5.319

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.